3-Hydroxy-2-methylpyridineCAS# 1121-25-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1121-25-1 | SDF | Download SDF |
PubChem ID | 70719 | Appearance | Powder |
Formula | C6H7NO | M.Wt | 109.13 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-methylpyridin-3-ol | ||
SMILES | CC1=C(C=CC=N1)O | ||
Standard InChIKey | AQSRRZGQRFFFGS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C6H7NO/c1-5-6(8)3-2-4-7-5/h2-4,8H,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 3-Hydroxy-2-methylpyridine could as a promising molecular scaffold for the future development of novel fibrillization inhibitors. |
Kinase Assay | Ortho-methylated 3-hydroxypyridines hinder hen egg-white lysozyme fibrillogenesis.[Pubmed: 26169912 ]Sci Rep. 2015 Jul 14;5:12052.Protein aggregation with the concomitant formation of amyloid fibrils is related to several neurodegenerative diseases, but also to non-neuropathic amyloidogenic diseases and non-neurophatic systemic amyloidosis. Lysozyme is the protein involved in the latter, and it is widely used as a model system to study the mechanisms underlying fibril formation and its inhibition. Several phenolic compounds have been reported as inhibitors of fibril formation. However, the anti-aggregating capacity of other heteroaromatic compounds has not been studied in any depth. |
3-Hydroxy-2-methylpyridine Dilution Calculator
3-Hydroxy-2-methylpyridine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 9.1634 mL | 45.8169 mL | 91.6338 mL | 183.2677 mL | 229.0846 mL |
5 mM | 1.8327 mL | 9.1634 mL | 18.3268 mL | 36.6535 mL | 45.8169 mL |
10 mM | 0.9163 mL | 4.5817 mL | 9.1634 mL | 18.3268 mL | 22.9085 mL |
50 mM | 0.1833 mL | 0.9163 mL | 1.8327 mL | 3.6654 mL | 4.5817 mL |
100 mM | 0.0916 mL | 0.4582 mL | 0.9163 mL | 1.8327 mL | 2.2908 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Endoxifen
Catalog No.:BCC7761
CAS No.:112093-28-4
- p-Vinylphenyl O-[beta-D-apiofuranosyl-(1-6)]-beta-D-glucopyranoside
Catalog No.:BCN1619
CAS No.:112047-91-3
- OctMAB
Catalog No.:BCC7893
CAS No.:1120-02-1
- Docosanoic acid
Catalog No.:BCC8952
CAS No.:112-85-6
- Oleic acid
Catalog No.:BCN7159
CAS No.:112-80-1
- Methyl linoleate
Catalog No.:BCN8137
CAS No.:112-63-0
- Methyl Oleate
Catalog No.:BCN8306
CAS No.:112-62-9
- Methyl Stearate
Catalog No.:BCN8309
CAS No.:112-61-8
- Methyl hexadecanoate
Catalog No.:BCN8290
CAS No.:112-39-0
- Acetic acid octyl ester
Catalog No.:BCN8303
CAS No.:112-14-1
- 2-Undecanone
Catalog No.:BCN8461
CAS No.:112-12-9
- Quetiapine fumarate
Catalog No.:BCN5339
CAS No.:111974-72-2
- (S)-(+)-Modafinic acid
Catalog No.:BCC5158
CAS No.:112111-44-1
- (R)-(-)-Modafinic acid
Catalog No.:BCC5157
CAS No.:112111-45-2
- Ikshusterol 3-O-glucoside
Catalog No.:BCN6001
CAS No.:112137-81-2
- DMAP
Catalog No.:BCC2842
CAS No.:1122-58-3
- Pam3CSK4
Catalog No.:BCC6245
CAS No.:112208-00-1
- 14,15-Didehydrovincamenine
Catalog No.:BCN6002
CAS No.:112219-48-4
- 16-O-Methyl-14,15-didehydroisovincanol
Catalog No.:BCN1618
CAS No.:112237-71-5
- Stigmastane-3,6-diol
Catalog No.:BCN6003
CAS No.:112244-29-8
- (S)-tert-Leucinol
Catalog No.:BCN8367
CAS No.:112245-13-3
- 20(R)-Ginsenoside Rh2
Catalog No.:BCN2484
CAS No.:112246-15-8
- H-Asp(OcHex)-OH
Catalog No.:BCC2887
CAS No.:112259-66-2
- BRL 52537 hydrochloride
Catalog No.:BCC6751
CAS No.:112282-24-3
Ortho-methylated 3-hydroxypyridines hinder hen egg-white lysozyme fibrillogenesis.[Pubmed:26169912]
Sci Rep. 2015 Jul 14;5:12052.
Protein aggregation with the concomitant formation of amyloid fibrils is related to several neurodegenerative diseases, but also to non-neuropathic amyloidogenic diseases and non-neurophatic systemic amyloidosis. Lysozyme is the protein involved in the latter, and it is widely used as a model system to study the mechanisms underlying fibril formation and its inhibition. Several phenolic compounds have been reported as inhibitors of fibril formation. However, the anti-aggregating capacity of other heteroaromatic compounds has not been studied in any depth. We have screened the capacity of eleven different hydroxypyridines to affect the acid-induced fibrillization of hen lysozyme. Although most of the tested hydroxypyridines alter the fibrillation kinetics of HEWL, only 3-Hydroxy-2-methylpyridine, 3-hydroxy-6-methylpyridine and 3-hydroxy-2,6-dimethylpyridine completely abolish fibril formation. Different biophysical techniques and several theoretical approaches are combined to elucidate their mechanism of action. O-methylated 3-hydroxypyridines bind non-cooperatively to two distinct but amyloidogenic regions of monomeric lysozyme. This stabilises the protein structure, as evidenced by enhanced thermal stability, and results in the inhibition of the conformational transition that precedes fibril assembly. Our results point to o-methylated 3-hydroxypyridines as a promising molecular scaffold for the future development of novel fibrillization inhibitors.